Evaluates efficacy of everolimus in autoimmune hepatitis, suggesting a potential rescue therapy option.
Background and objective: In autoimmune hepatitis (AIH), some patients fail to respond to first-line immunosuppression or develop treatment-related malignancies requiring alternative treatments. Rapamycin (mTOR) inhibitors may represent an alternative treatment strategy; however, long-term follow-up [for full text, please go to the a.m. URL]
No takes yet. Share an insight, caveat, or question.
Seltsam et al. (2026) studied this question.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: